A clinically aggressive, polymorphic, polyclonal posttransplantation lymphoproliferative disorder.
Posttransplantation lymphoproliferative disorders (PTLD) have been divided, based on morphology, into polymorphic and monomorphic types, since findings in the literature reveal that polymorphic PTLD more likely responds to reduced immunosuppression. We report a clinically aggressive, polymorphic (and polyclonal) PTLD despite reduced immunosuppression and discuss possible therapeutic options. In addition, our case suggests that cytogenetic studies may be useful in determining prognosis when DNA molecular techniques do not detect monoclonality.
Department of Pathology, St. Louis University Health Sciences Center, MO 63104, USA.
C H
CH
Dunphy
J R
JR
Batanian
D000782:Aneuploidy; D019070:Cell Lineage; D002869:Chromosome Aberrations; D005434:Flow Cytometry; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D016130:Immunophenotyping; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007621:Karyotyping; D008198:Lymph Nodes / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged